로딩 중…
지수 로딩 중…
Yarrow Bioscience Inc. Common Stock
YARW· NASDAQ
$20.00+2.20%
2026-10-29
Financials
Valuation Metrics
Yarrow Bioscience Inc. Common Stock's Market Cap is $17M. At end of 2025 it was $0M. Ranked #3104 of 3,115 in US market (top 100%), #1462 of 1,472 on NASDAQ (top 99%) by Market Cap.
Investment Metrics(as of 2026-10-29)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $17M | US#3,104/3,115 |
| Revenue | $482000.00 | US#2,854/3,115 |
| Net Income | $-19M | US—/3,115 |
| Total Assets | $24M | US#3,080/3,115 |
| Net Assets | $22M | US#2,883/3,115 |
| Employees | 10 | US#2,770/3,115 |
| Value | ||
| P/B | 0.78x | US#216/3,115 |
| P/S | 35.68x | US#2,896/3,115 |
| FCF Yield | -98.47% | US—/3,115 |
| Profitability | ||
| ROE | -84.80% | US#2,768/3,115 |
| ROA | -79.26% | US#3,039/3,115 |
| Op. Margin | -4134.65% | US#2,831/3,115 |
| Revenue Growth | 13.77% | US#974/3,115 |
| Financial Health | ||
| Debt Ratio | 6.99% | US#62/3,115 |
| Total Debt | $0.00 | US—/3,115 |
| FCF | $-17M | US#2,404/3,115 |
| Cash | $23M | US#2,827/3,115 |
| Current Ratio | 15.26x | US#163/3,115 |
| Performance | ||
| 1Y Return | 15.41% | US#1,360/3,115 |
| 1M Return | -17.32% | US#2,868/3,115 |
| From 52W High | -57.40% | US#2,848/3,115 |
| 1Y MDD | -60.33% | US#2,726/3,115 |
| Trading | ||
| Volume | 210,575 shares | US#2,502/3,115 |
| Trading Value | $4M | US#2,606/3,115 |
| Per Share | ||
| EPS | $-21.76 | US—/3,115 |
| BPS | $25.66 | US#1,021/3,115 |
Company Info
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).